Allogene Therapeutics
Joseph Walsh has a comprehensive background in quality control and logistics within the biopharmaceutical industry, currently serving as a QC Analyst II in Sample Management at Allogene Therapeutics since July 2021. Prior positions include a QC Analyst in Sample Management at the same company, a Manufacturing Logistics Coordinator at Boehringer Ingelheim from October 2018 to July 2021, and a Consulting Utility Forester at ACRT from March 2017 to October 2018. Joseph Walsh holds a Bachelor of Science degree in Environmental Studies from San Jose State University, obtained between 2013 and 2016, and completed transfer studies in Environmental Studies at Ohlone College from 2010 to 2013.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.